Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol add-on therapy for tuberous sclerosis complex-associated seizures
NL-OMON47292Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in tuberous sclerosis complex (TSC), sponsored by GW Pharmaceuticals. Primary endpoints: Change in number of TSC-associated seizures and Long-term safety by adverse events. Started Dec 2017; status: completed.
02
Drugs
cannabidiol
03
Conditions
tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NL-OMON47292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47292.